Clodagh O’Shea (Salk)
A veteran oncology startup crew is making a very serious bet that they’ve found the key to unlocking the promise of oncolytic viruses
Five years ago, when Amgen ushered the oncolytic virus T-Vec over the finish line at the FDA, 2 things seemed completely clear in short order …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
